quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:30:11·157d
INSIDERFiling
LAVA Therapeutics N.V. logo

Director Wilson Karen J returned 10,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

LVTX· LAVA Therapeutics N.V.
Health Care
Original source

Companies

  • LVTX
    LAVA Therapeutics N.V.
    Health Care

Recent analyst ratings

  • Dec 12UpdateLeerink Partners$2.00
  • Dec 11UpdateJMP Securities-
  • Oct 25UpdateH.C. Wainwright$9.00
  • Nov 16UpdateSVB Leerink$20.00
  • Aug 17UpdateSVB Leerink$24.00

Related

  • SEC153d
    Amendment: SEC Form 25-NSE/A filed by LAVA Therapeutics N.V.
  • SEC154d
    SEC Form S-8 POS filed by LAVA Therapeutics N.V.
  • SEC154d
    SEC Form S-8 POS filed by LAVA Therapeutics N.V.
  • SEC154d
    Amendment: SEC Form SC 14D9/A filed by LAVA Therapeutics N.V.
  • SEC154d
    LAVA Therapeutics N.V. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Leadership Update
  • SEC154d
    Amendment: SEC Form SC TO-T/A filed by LAVA Therapeutics N.V.
  • PR154d
    XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
  • INSIDER157d
    Chief Financial Officer Powell Fred M returned 65,000 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022